MedTrace Logo

Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

NCT02348918 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2018-12-07

Study results available
· View outcomes & findings →

Summary

A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema

Conditions

Interventions

DRUG

Luminate 1.0mg

DRUG

Luminate 2.0mg

DRUG

Luminate 3.0mg

DRUG

Avastin

DRUG

Luminate 0.5mg

Sponsors & Collaborators

  • Trial Runners, LLC

    collaborator OTHER

  • Duke University

    collaborator OTHER

  • Allegro Ophthalmics, LLC

    lead INDUSTRY

Principal Investigators

  • Vicken Karageozian · Cheif Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-13
Primary Completion
2017-05-16
Completion
2017-06-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02348918 on ClinicalTrials.gov